Mode
Text Size
Log in / Sign up
Phase 3 Completed N=102 Randomized Treatment

Surgical Site Infections After Liver Transplantation Based on Perioperative Antibiotics

Source: ClinicalTrials.gov NCT02717273 ↗
Enrolled (actual)
102
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcomePrimary: Number of Subjects With Development of Surgical Site Infections — 9; 13 Participants
◆ Published Evidence
Established
20citations · ~3 / year
Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients.
The Cochrane database of systematic reviews · 2020 · Open access · Likely link

Summary

This study will be to prospectively determine differences in Surgical Site Infection (SSI) if a prolonged course of post-operative antibiotics are used following liver transplantation.

Linked Publications

  • Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients.
    The Cochrane database of systematic reviews · 2020 · 20 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Subjects With Development of Surgical Site Infections
9; 13
SECONDARY
Number of Subjects With Post-operative Fever
6; 7
SECONDARY
Number of Subjects With Elevated White Blood Count (WBC)
42; 41
SECONDARY
Number of Subjects With Nosocomial Infection
8; 11
SECONDARY
Length of Hospital Stay
7.5; 7.5
SECONDARY
Number of Subjects With Graft Loss
7; 6
SECONDARY
Number of Subjects With Mortality
1; 1

Eligibility Criteria

Inclusion Criteria

  • All patients ≥ 18 years of age.
  • Eligible for liver transplantation by UVA standard protocol.
  • First-time transplantation.
  • No active infections - requiring antibiotics - excluding antifungals.

Exclusion Criteria

  • All patients < 18 years of age.
  • Previous liver transplantation.
  • Active infections - requiring antibiotics.
  • Allergy to all standard peri-operative antibiotics (piperacillin/tazobactam or UVA standard alternatives for Penicillin allergic patients: ciprofloxacin and vancomycin).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02717273) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search